Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium
Status:
Completed
Trial end date:
2020-09-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn what effects, good and/or bad, Buparlisib has on
advanced urothelial cancer. Buparlisib is a pill that works by shutting down some of the
signals in cancer cells that make tumors grow. It is being tested in patients in research
studies such as this one. As of 2010, more than 80 patients with various types of cancer have
received treatment with Buparlisib in research studies.
This clinical research study is divided into two parts. The goal of the first part of this
study is to learn if the study drug Buparlisib can shrink or slow the growth of cancer in
patients with urothelial tumors. The goal of the second part of this study is to learn if the
study drug Buparlisib can shrink or slow the growth of urothelial tumors in patients known to
have certain genetic alterations that cause these types of tumors. The study doctor will
inform the patient which part of the study is currently enrolling participants. Participants
in both parts of the study will receive the same treatment and tests.
The safety of this drug will also be studied in both parts. The physical state, changes in
the size of the tumor, and laboratory findings taken while on-study will help us decide if
Buparlisib is safe and effective.